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Abstract
Objectives. Hospital admissions for gout flares have increased dramatically in recent years, despite
widely available, effective medications for the treatment and prevention of flares. We conducted a sys-
tematic review to evaluate the effectiveness and implementation of interventions in patients hospitalized
for gout flares.
Methods. A search was conducted in MEDLINE, Embase and the Cochrane library, from database in-
ception to 8 April 2021, using the terms ‘gout’ and ‘hospital’ and their synonyms. Studies were
included if they evaluated the effectiveness and/or implementation of interventions during hospital
admissions or emergency department attendances for gout flares. Risk of bias assessments were per-
formed for included studies.
Results. Nineteen articles were included. Most studies were small, retrospective analyses performed in
single centres, with concerns for bias. Eleven studies (including five randomized controlled trials)
reported improved patient outcomes following pharmacological interventions with known efficacy in
gout, including allopurinol, prednisolone, NSAIDs and anakinra. Eight studies reported improved out-
comes associated with non-pharmacological interventions: inpatient rheumatology consultation and a
hospital gout management protocol. No studies to date have prospectively evaluated strategies
designed to prevent re-admissions of patients hospitalized for gout flares.
Conclusion. There is an urgent need for high-quality, prospective studies of strategies for improving
uptake of urate-lowering therapies in hospitalized patients, incorporating prophylaxis against flares and
treat-to-target optimization of serum urate levels. Such studies are essential if the epidemic of hospital
admissions from this treatable condition is to be countered.
Key words: gout, hospital, admission, emergency, inpatient, prevention, urate-lowering therapy, allopurinol,
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Introduction
Gout is characterized by recurrent flares of joint pain
and swelling, which can necessitate hospital admission
when severe. Highly effective, low-cost medications are
available for the treatment of gout flares: colchicine,
NSAIDs and corticosteroids [1–3]. Flares can be pre-
vented by urate-lowering therapies (ULTs), of which allo-
purinol is the most widely used [1–3]. British Society for
Rheumatology key messages
. There is a paucity of high-quality studies of interventions in patients hospitalized for gout flares.
. No studies have prospectively evaluated strategies for optimizing urate-lowering therapies and preventing re-
admissions following hospitalizations.
. These studies are urgently needed if the epidemic of gout admissions is to be halted.
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Rheumatology (BSR) and EULAR guidelines recommend
offering ULT to all patients with gout, with up-titration to
achieve serum urate (SU) levels of 300–360 micromol/l
(5–6 mg/dl), to facilitate crystal dissolution [1, 2]. The
ACR gout management guideline was recently updated
to conditionally recommend initiation of ULT during
flares, rather than delayed initiation of ULT after flare
resolution [3].
Despite effective treatments, hospitalizations for gout
flares have increased dramatically: doubling in the USA
between 1993 and 2011, from 4.4 to 8.8 admissions per
100 000 adults, respectively [4]; doubling in Canada be-
tween 2000 and 2011, from 3.8 to 7.6 admissions per
100 000 adults [5]; and increasing by 58.4% in England
between 2006 and 2017, from 7.9 to 12.5 admissions
per 100 000 adults [6]. This contrasts with the decline in
hospitalizations from RA [4–6]. There are multiple contri-
buting factors to the epidemic of gout hospitalizations:
the prevalence of gout has increased in Western coun-
tries in recent years on a background of an ageing
population with rising prevalences of obesity and meta-
bolic syndrome [7, 8]; the management of gout is fre-
quently suboptimal in primary care, rheumatology clinics
and inpatient settings, and only a minority of patients
achieve the SU levels required to prevent flares [8, 9].
Hospital admissions provide a unique opportunity to
engage patients in shared decision-making and begin
the process of establishing optimal ULT. What is not
known is how best to implement evidence-based treat-
ments during hospitalizations for gout. Such strategies
are essential if the rising number of gout admissions is
to be countered. The objective of this systematic review
was to evaluate the evidence for the effectiveness of
interventions in patients hospitalized with gout.
Methods
Database search strategy and eligibility criteria
A systematic literature search was conducted using the
MEDLINE, Embase and Cochrane library databases.
Studies were eligible if they evaluated the effectiveness
and/or implementation of interventions in patients aged
18 years during hospital admissions or emergency de-
partment (ED) attendances for gout flares. Studies
involving patients with secondary admission diagnoses
of gout were also eligible for inclusion. Search terms uti-
lized included ‘gout’, ‘hospital’ and their synonyms (see
Supplementary Data S1 for the full list of search terms
used, available at Rheumatology online). Interventions
could be pharmacological or non-pharmacological, for
example implementation of a management protocol.
Outcomes were selected following consensus discus-
sion around measures felt to be important in the man-
agement and follow-up of hospitalized gout patients.
Primary outcome measures were the frequency of ad-
mission to hospital and/or ED attendances for gout
flares; the frequency of gout flares following the inter-
vention; and length of stay in hospital. Additional out-
comes of interest were time to resolution of the initial
gout flare; time to initiation of treatment; time to first
flare re-occurrence; change in pain scores; change in in-
flammatory markers (CRP, ESR); adverse event rates;
and the proportions of patients (i) undergoing joint aspir-
ation and/or steroid injection during admission, (ii) with a
SU level measured during admission, (iii) prescribed ULT
on or after discharge, (iv) with discharge plans and/or
outpatient follow-up for gout, or (iv) attaining target SU
levels.
An initial search of databases was performed on 10
February 2021, followed by a re-run of the search on 8
April 2021 to ensure additional relevant studies were
included. Eligible study types were randomized con-
trolled trials (RCTs), non-randomized controlled trials,
prospective cohort studies, retrospective cohort studies,
case–control studies, and case series reporting at least
five patients. Case reports were excluded.
The study was performed in accordance with the pre-
ferred reporting system for systematic reviews (PRISMA)
[10], and was registered with the international prospect-
ive register of systematic reviews (PROSPERO registra-
tion ID: CRD42021245672).
Data extraction
Two reviewers (M.D.R. and B.D.C.) screened manuscript
titles and abstracts. Full texts of relevant studies were
reviewed against the eligibility criteria. Data extraction
was performed by two reviewers (M.D.R. and B.D.C.).
Study characteristics extracted included study type, par-
ticipant numbers, demographics, disease characteris-
tics, interventions, and outcome measures as detailed
above. Discrepancies arising between reviewers during
study selection or data extraction were resolved through
consensus discussion, with involvement of a third re-
viewer (J.B.G.) where necessary.
Risk of bias determination
A bias assessment was conducted by two reviewers
(M.D.R. and B.D.C.). The Cochrane Risk of Bias 2
(RoB 2) tool was used for RCTs [11]. the Newcastle–
Ottawa Scale (NOS) was used for non-randomized
studies [12]. Discrepancies were resolved through
consensus discussion, with involvement of a third re-
viewer (J.B.G.) where necessary.
Data synthesis
A narrative synthesis was performed due to the small
number of eligible studies and the differing interventions




The systematic literature search identified 4197 studies, of
which 19 were included (Fig. 1 and Table 1 [13–31]). Of
the included studies, five were RCTs, one was a prospect-
ive cohort study and 13 were retrospective analyses.
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Eleven studies assessed outcomes after pharmacological
interventions: ULT (six studies), prednisolone vs indometh-
acin (two studies), indomethacin vs ketorolac (one study),
anakinra (one study), and adrenocorticotropic hormone
(ACTH) (one study). Eight studies assessed outcomes after
non-pharmacological interventions: inpatient rheumatology
consultation (seven studies), and an inpatient gout man-
agement protocol (one study). Of the five included RCTs,
one was deemed to be at high risk of bias [13], three had
some concerns for bias [14–16], and one was at low risk
of bias [17] (Supplementary Fig. S1, available at
Rheumatology online). All non-randomized studies had po-
tential sources of bias (Supplementary Fig. S2, available at
Rheumatology online).
Pharmacological treatments for gout flares in
hospitalized patients
Two RCTs compared NSAIDs and corticosteroids in
patients presenting to EDs with gout flares [14, 15]. In
both studies, participants were randomized to receive
prednisolone 30 mg daily for 5 days or indomethacin
50 mg three times daily for 2 days followed by indometh-
acin 25 mg daily for 3 days. All participants received
concomitant paracetamol (acetaminophen) 1 g, up to 4
times daily as required.
In the larger of the two studies, 416 participants from
four EDs were recruited and randomized, of whom 376
participants completed the study [14]. In intention-to-
treat and per-protocol analyses, reductions in pain
scores were similar between the prednisolone and indo-
methacin arms, both in ED and by day 14. No serious
adverse events occurred with either intervention. Minor
adverse events were more frequent with indomethacin
than prednisolone during the ED stays (19% vs 6%; P <
0.001) but not subsequently. Length of stay in ED did
not differ between the study arms (5 h in both cohorts).
There were no significant differences in the proportion of
participants returning to ED within 14 days.
FIG. 1 PRISMA flowchart of studies identified from the systematic literature search. Adapted from: Moher D, Liberati
A, Tetzlaff J, Altman DG, The PRISMA group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 2009;6:e1000097. ED: emergency department
Records idenfied through database 
searching 
(n=4,197) 






Full-text arcles assessed for 
eligibility 
(n=44) 
Full-text arcles excluded 
(n=25), with reasons: 
• Not involving hospitalised 
or ED paents (n=12) 
• No intervenon (n=5) 
• No relevant endpoint (n=1) 
• Non-gout diagnoses (n=2) 
• Ineligible study type (n=5) 
Studies included in narrave 
synthesis 
(n=19) 
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In the second RCT (n¼ 90), the rate of decrease in
pain on activity from day 1 to day 14 of follow-up was
greater for prednisolone than for indomethacin
(2.9 mm/day vs 1.7 mm/day, respectively; mean dif-
ference: 1.2 mm/day; 95% CI: 0.4, 2.0 mm/day; P ¼
0.003) [15]; however, the absolute differences in pain
scores between the interventions were modest, and
both cohorts reached the same VAS score by day 14.
The indomethacin arm experienced more adverse
events than the prednisolone arm (63% vs 27%, re-
spectively; P < 0.05), particularly gastrointestinal bleed-
ing events requiring hospitalization (5 vs 0 events,
respectively). Flare relapse rates did not differ signifi-
cantly between the indomethacin and prednisolone arms
(8 vs 5 flares, respectively).
An additional RCT compared the analgesic efficacy of
two NSAIDs—oral indomethacin 50 mg, single dose, and
i.m. ketorolac 60 mg, single dose—in patients (n¼20)
presenting to two EDs with gout flares [13]. Analgesic
efficacy was not significantly different between the treat-
ments at 2 h after administration (64% vs 68% reduction
in pain scores, respectively). With indomethacin, pain
scores remained low at 24 h after treatment. With ketor-
olac, mean pain scores rebounded after 6 h (from 1.4 to
2.8 on a 0–5 Wong-Baker FACESV
R
Rating Scale; P
<0.05), followed by improvements thereafter, such that
scores were not significantly different between indo-
methacin and ketorolac by 24 h after treatment. No ad-
verse effects were reported with either treatment.
A single-centre retrospective study reported out-
comes for 26 hospitalized patients who received ana-
kinra for treatment-resistant flares, defined as an
inadequate response to colchicine, NSAIDs or cortico-
steroids and/or contraindications to these medications
[18]. Several anakinra dosing regimens were used, de-
pending on each patient’s weight, renal function, extent
of joint involvement and response to initial treatment.
Multiple courses of anakinra were administered in seven
patients, five of whom received the additional courses
during different hospital admissions. There was no com-
parator group. Improvements in pain scores to below 3
on a 10-point scale were observed in 67% of anakinra
courses within 24 h of treatment and in 85% by 48 h.
Symptom resolution occurred in 73% of patients by day
5; by day 10, all but one patient had fully responded.
Anakinra was well tolerated, with no attributable adverse
events.
Another single-centre retrospective study reported on
the use of i.m. ACTH 1 mg in 181 hospitalized gout
patients [19]. There was no comparator group. Response
to ACTH, defined as attenuation of signs of inflammation
and no requirement for corticosteroids, NSAIDs, colchicine
or analgesics for 2 days, was observed in 78% of partici-
pants. Most non-responders were re-treated with a further
injection of ACTH and, of these, 83% responded. A repeat
flare was suffered by 11% of participants, after a median
of 4 days. Few attributable adverse events were reported,
with local injection site reactions observed in 2% of
participants.
ULT for the prevention of gout flares in hospitalized
patients
The benefits of ULT on hospitalizations and ED attend-
ances have been evaluated in retrospective analyses. In
a single-centre study of US veterans (n¼ 250) attending
ED for gout flares, use of ULT was associated with
fewer ED visits for gout flares (determined retrospective-
ly), relative to those with no use of ULT (P ¼0.02; effect
size not provided) [20].
In a case–control study, patients (n¼ 48) hospitalized
for gout at least twice in the preceding year were less
likely to have received allopurinol than age-, sex- and
ethnicity-matched controls with gout but without
hospital admissions (OR 0.06; 95% CI: 0.02, 0.20; P <
0.0001) [21]. The median allopurinol dosages were lower
in patients with recurrent admissions than in the
comparator group (200 mg vs 300 mg, respectively; P ¼
0.0019), and hospitalized patients were less likely to
have been prescribed colchicine prophylaxis (OR 0.39;
95% CI: 0.17, 0.89; P ¼0.039). Relative to those without
recurrent admissions, patients with recurrent admissions
had more comorbidities (6.5 vs 5.1; P ¼0.011), more
comorbid heart disease (71% vs 46%; P ¼0.013), higher
rates of erosive gout (89% vs 46%; P ¼0.0007) and
more tophaceous disease (65% vs 42%; P ¼0.038).
Patients with recurrent hospital admissions for gout
were also more likely to have been admitted for other
conditions in the preceding year (5.8 vs 0.6 admissions;
P <0.0001).
In a retrospective study of patients hospitalized for
gout flares while receiving allopurinol (n¼59), dose
reductions (or discontinuations) of allopurinol during
admissions were associated with higher rates of flares in
the 3 months following discharge than admissions during
which allopurinol doses were unchanged or increased
(53% vs 22%; P ¼0.03) [22]. The primary reason pro-
vided for the allopurinol dose reductions/discontinua-
tions was acute kidney injury, which was present in a
higher proportion of this group than that of the com-
parator group (60% vs 36%). Patients in the dose-
reduced/discontinued cohort were less likely to have
received flare prophylaxis at discharge than the dose-
unchanged/increased cohort (60% vs 27%; P-value not
specified), which may have contributed to the observed
differences in post-discharge flares.
Whether to initiate ULT during a gout flare has been
evaluated in three studies that included participants
recruited from EDs and inpatient settings [16, 17, 23]. In
an RCT, 31 participants were recruited from EDs and
rheumatology clinics within 72 h of initial therapy for a
gout flare and randomized to receive allopurinol 100 mg
daily (up-titrated to 200 mg daily after 14 days) or pla-
cebo [16]. Treatment for the flare was determined by the
treating physician, with corticosteroids utilized in over
80% of participants. Both study arms received prophy-
lactic low-dose colchicine. The primary end point of
time to resolution of the flares was not significantly dif-
ferent between the allopurinol and the placebo arms
(15.4 days vs 13.4 days, respectively; P ¼0.50). It is of
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note, however, that post-hoc power calculations sug-
gested 116 subjects per arm were required in order to
have demonstrated a significant difference in this end
point. Pain and physician global assessment scores
declined rapidly in both study arms. As might be
expected, SU levels were significantly lower in the allo-
purinol arm than the placebo arm at study completion
(6.4 mg/dl vs 8.3 mg/dl; P ¼0.012).
In another single-centre RCT, 57 participants recruited
from EDs, wards and outpatient clinics within 7 days of
onset of gout flares were randomized to receive allopur-
inol 300 mg daily or placebo for 10 days [17]. After day
10, all participants received open-label allopurinol
300 mg daily. All participants received indomethacin
50 mg three times daily for 10 days and colchicine
0.6 mg twice daily for 90 days. The co-primary end point
of participant-reported joint pain normalized rapidly in
both study arms, with no significant differences between
arms from days 1 to 10. Self-reported new or recurrent
gout flares did not differ significantly between study
arms by day 30 (7.7% in the early initiation group vs
12.0% in the delayed initiation group; P ¼0.61), despite
rapid decreases in SU levels in the early initiation group.
Similarly, in a retrospective study involving patients
recruited from hospital or outpatient settings, more rapid
attainment of target SU levels was observed with imme-
diate vs delayed initiation of ULT (2.5 vs 3.8 months, re-
spectively; P ¼0.004) [23]. Repeat flares occurred more
frequently in the immediate commencement cohort than
in the delayed commencement cohort in the 12 weeks
after the initial flare, but were comparable beyond this
point.
Non-pharmacological interventions for hospitalized
gout patients
Gaps in healthcare providers’ knowledge of gout are an
important barrier to optimal care [32]. To address this,
one study retrospectively analysed outcomes before
and after the introduction of an evidence-based protocol
for non-rheumatologists treating hospitalized patients
with gout flares [24]. This protocol recommendations to
continue baseline ULT, initiate anti-inflammatory medi-
cations, perform joint aspiration, and involve rheumatol-
ogists in cases of diagnostic uncertainty. Following
introduction of the protocol, more patients continued
their baseline allopurinol (56% vs 20%; P ¼0.01), treat-
ment delays were reduced (5% vs 33%; P <0.001), and
rheumatology consults increased (52% vs 34%; P
¼0.01). Admission durations were shorter following
introduction of the protocol, albeit non-significantly
(10 days vs 11.5 days; P ¼0.3).
Six retrospective studies and one prospective cohort
study have reported outcomes for gout admissions
involving inpatient rheumatology consultation, relative to
those without inpatient rheumatology consultation
[25–31]. The proportion of admissions with rheumatology
input varied widely between studies, from 17% to 76%,
averaging 40% across all studies. Rheumatology input
was consistently associated with more intra-articular
joint aspirations and/or steroid injections [26–31]. Those
receiving rheumatology input were more likely to have
had SU levels measured [28, 30, 31] and more likely to
have received outpatient rheumatology follow-up
[26–28], relative to patients without rheumatology input.
Four studies reported significant associations between
rheumatology consultation and increased utilization of
ULT [25, 27, 29, 30]. No studies reported significant
associations between rheumatology consultation and
length of stay in hospital [27–30].
Discussion
In this systematic review, we identified 19 studies
reporting associations between interventions and
improved outcomes for patients hospitalized with gout.
Most were small, retrospective analyses performed in
single centres, with concerns for bias. The majority
reported on pharmacological interventions known to be
effective in the treatment and prevention of gout flares.
However, no prospective studies to date have evaluated
packages of care designed specifically to prevent further
admissions in patients hospitalized for gout flares. There
is an urgent need for such studies if the inexorable rise
in hospitalizations from this treatable condition is to be
stopped.
Hospitalizations provide an opportunity for clinicians
to educate patients about gout, engage them in
shared decision-making, facilitate self-management
and introduce optimal ULT. Sustained reductions in
SU levels with optimal use of ULT halts crystal forma-
tion and causes dissolution of existing crystals, there-
by preventing flares, shrinking tophi and protecting
against long-term joint damage [1, 33]. We identified
two retrospective analyses that reported associations
between the use of ULT and the prevention of hospi-
talizations and ED attendances [20, 21]. Despite this,
most patients do not receive ULT prior to, during or
after their admissions [25, 30]. Initiation of ULT is fre-
quently deferred until after discharge due to concerns
that initiation of ULT will prolong or worsen the exist-
ing flare [17]. Post-discharge recommendations to
commence ULT are frequently not acted upon [25],
leaving patients at risk of re-admission. The recently
updated ACR gout management guideline challenged
this practice by conditionally recommending initiation
of ULT during flares, supported by their patient panel
who advised that the flare may provide additional mo-
tivation for patients to commence ULT, although also
highlighting the potential for information overload,
which could conflate flare management and long-term
ULT [3]. ACR’s recommendation is backed by the find-
ings of four studies [16, 17, 23, 34], three of which
recruited hospitalized patients or patients attending
ED. These studies demonstrated ways of mitigating
the risk of flare aggravation while commencing ULT,
including gradual up-titration of ULT from a low start-
ing dose and concomitant use of anti-inflammatory
medications. Widespread implementation of ACR’s
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TABLE 1 Summary of characteristics of studies included within the systematic review, highlighting key outcome meas-
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recommendation in patients hospitalized for gout could
greatly improve uptake of ULT in this high-risk population
and prevent recurrent admissions. Admission affords the
time to provide information to patients about both flare
management and ULT, addressing the concern of the
ACR guideline patient panel.
Only a minority of patients who commence ULT
achieve the target SU levels necessary to prevent flares
and hospitalizations [8, 9]. Very few studies identified in
our search reported on the attainment of target SU lev-
els, and no studies directly evaluated approaches for
achieving target SU levels after discharge. Seven stud-
ies reported improved outcomes with involvement of
rheumatologists during hospitalizations, emphasizing the
importance of specialist input in facilitating appropriate



















































































































ACTH: adrenocorticotropic hormone; ED: emergency department; OD: once daily; OR: odds ratio; RCT: randomized con-
trolled trial; SU: serum urate; TDS: three times daily; ULT: urate-lowering therapy; VAS: visual analogue scale for pain.
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consultation does not necessarily equate to the attain-
ment of target SU levels; a recent UK national audit of
gout management in outpatient rheumatology clinics
reported that target SU levels were achieved in less
than half of patients [9]. Furthermore, of the relevant
studies in our review, rheumatology input occurred in
only 40% of admissions for gout flares, suggesting strat-
egies are needed to increase consultation rates.
Several studies in community settings have evaluated
interventions aimed at increasing attainment of target
SU levels [33, 35–38], many of which could be applied
to hospitalized patients. In an RCT of 517 patients with
gout in primary care, research nurses were trained to
deliver an individualized package of care, incorporating
patient education, shared decision-making, and follow-
up visits to guide ULT dose escalation [33]. At 1 year,
95% of patients who received the intervention achieved
target SU levels, compared with 30% receiving usual
GP care. Gout flares were less frequent following the
intervention, and patients’ quality of life improved signifi-
cantly. In a site-randomized study of 1463 patients
receiving new prescriptions for allopurinol, pharmacist-
led treat-to-target optimization of allopurinol was com-
pared with usual care [39]. The intervention was deliv-
ered through an interactive voice–response system,
incorporating reminders and encouragement for
patients. At 1 year, patients receiving the intervention
were more likely to have been adherent to allopurinol
(50% vs 37%; OR 1.68; P <0.001) and more likely to
have achieved SU targets (30% vs 15%; OR 2.37; P
<0.001) than those receiving usual care. In another
study, an electronic visit tool was used to facilitate pa-
tient–clinician interaction, treat-to-target ULT, and edu-
cation for outpatients [38]. Significantly more patients
achieved target SU levels following this intervention,
relative to a historical cohort (64% vs 34%, respectively;
P <0.01). Aspects of all of these interventions could be
incorporated into a care package, delivered by nurses
or pharmacists, with the aim of establishing patients on
dose-optimized ULT following discharge from hospital.
Many interventions that were associated with improved
outcomes for hospitalized patients are already included
within international gout management guidelines [1–3].
Poor healthcare provider understanding of the long-term
health consequences of gout and the importance of treat-
ment are important barriers to optimal care [32]. Strategies
to improve implementation of evidence-based interven-
tions in hospitalized patients are needed if outcomes are
to be improved and re-admissions prevented. In their
study of an inpatient gout management protocol based
upon EULAR guidelines, Kamaralaj et al. utilized three im-
plementation approaches: educational sessions for clini-
cians, electronic health record prompts, and advertising in
clinical settings [24]. Multipronged implementation
approaches are essential if interventions known to be ef-
fective in the management of gout are to be assimilated
into clinical practice [40]. Case-notereviews and process
mapping will help to identify barriers and facilitators of op-
timal admitted gout care and the necessary behavioural
changes [41]. Only then can interventions be selected to
address these barriers, alongside implementation
approaches tailored to the inpatient setting [42].
Our systematic review has several limitations, many of
which reflect the paucity of available data. Most included
studies had small participant numbers, with concerns for
bias. The majority of studies reported positive findings,
suggesting a degree of publication bias. Many were single-
centre analyses, which limits the generalizability of the find-
ings. Outcome measures varied widely between studies,
precluding direct comparisons and meta-analysis. This was
also reflected in the range of outcome measures selected
for our review, which were chosen on the basis of consen-
sus discussion rather than by using specific criteria, such
as the OMERACT criteria [43]. Although some outcomes
align with those within the OMERACT criteria, adoption of
these criteria in future studies would facilitate comparisons
of study outcomes. Similarly, diagnostic and inclusion crite-
ria varied substantially between studies, while verification
of diagnosis was not possible, which may have resulted in
a degree of misclassification bias. Many of the included
studies reported pooled results for primary and secondary
admission diagnoses of gout, despite differences between
these populations, and separate reporting of outcomes in
future studies may highlight the need for different manage-
ment strategies in these populations.
This systematic review highlights an urgent need for
prospective studies of strategies to prevent hospitaliza-
tions from gout. Gout is a highly treatable yet poorly man-
aged condition, and many admissions from gout are likely
to be preventable with better use of existing treatments.
Effective implementation of strategies designed to improve
uptake of ULT in hospitalized patients, alongside prophy-
laxis against flares and treat-to-target ULT optimization, is
essential if the epidemic of hospital admissions from this
treatable condition is to be countered.
Funding: This work is independent research supported
by a National Institute for Health Research (NIHR)
Doctoral Fellowship for M.D.R. (NIHR300967). The views
expressed in this publication are those of the authors
and not necessarily those of the NHS, the NIHR or the
Department of Health and Social Care.
Disclosure statement: J.B.G. receives speaker fees from
Abbvie, Biovitrum, BMS, Celgene, Chugai, Gilead,
Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Sobi and
UCB. M.D.R. has received honoraria and educational
grants from Janssen, Lilly, Menarini, Pfizer and UCB.
B.D.C. has received honoraria from Abbvie.
Data availability statement
The data underlying this article are available from
research articles in the public domain.
Supplementary data
Supplementary data are available at Rheumatology online.









atology/keab539/6319039 by Keele U
niversity user on 14 O
ctober 2021
References
1 Hui M, Carr A, Cameron S et al.; British Society for
Rheumatology Standards, Audit and Guidelines Working
Group. The British Society for Rheumatology guideline
for the management of gout. Rheumatology 2017;56:
1246.
2 Richette P, Doherty M, Pascual E et al. 2016 updated
EULAR evidence-based recommendations for the man-
agement of gout. Ann Rheum Dis 2017;76:29–42.
3 FitzGerald JD, Dalbeth N, Mikuls T et al. 2020 American
College of Rheumatology guideline for the management
of gout. Arthritis Care Res 2020;72:744–60.
4 Lim SY, Lu N, Oza A et al. Trends in gout and
rheumatoid arthritis hospitalizations in the United States,
1993–2011. JAMA 2016;315:2345–7.
5 Rai SK, Avina-Zubieta JA, McCormick N et al. Trends in
gout and rheumatoid arthritis hospitalizations in Canada
from 2000 to 2011. Arthritis Care Res 2017;69:758–62.
6 Russell MD, Yates M, Bechman K et al. Rising incidence
of acute hospital admissions due to gout. J Rheumatol
2020;47:619–23.
7 Dehlin M, Jacobsson L, Roddy E. Global epidemiology
of gout: prevalence, incidence, treatment patterns and
risk factors. Nat Rev Rheumatol 2020;16:380–90.
8 Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M.
Rising burden of gout in the UK but continuing
suboptimal management: a nationwide population study.
Ann Rheum Dis 2015;74:661–7.
9 Roddy E, Packham J, Obrenovic K, Rivett A, Ledingham
JM. Management of gout by UK rheumatologists: a
British Society for Rheumatology national audit.
Rheumatology (Oxford) 2018;57:826–30.
10 Moher D, Shamseer L, Clarke M et al.; PRISMA-P
Group. Preferred reporting items for systematic review
and meta-analysis protocols (PRISMA-P) 2015 state-
ment. Syst Rev 2015;4:1.
11 Higgins JP, Altman DG, Gotzsche PC et al.; Cochrane
Statistical Methods Group. The Cochrane Collaboration’s
tool for assessing risk of bias in randomised trials. BMJ
2011;343:d5928.
12 Wells GA, Shea B, O’Connell D et al. The Newcastle–
Ottawa Scale (NOS) for assessing the quality of
nonrandomised studies in meta-analyses. 2013. Ottawa,
ON: The Ottawa Hospital Research Institute. http://www.
ohri.ca/programs/clinical_epidemiology/oxford.asp (15
June 2021, date last accessed).
13 Shrestha M, Morgan DL, Moreden JM et al. Randomized
double-blind comparison of the analgesic efficacy of
intramuscular ketorolac and oral indomethacin in the
treatment of acute gouty arthritis. Ann Emerg Med 1995;
26:682–6.
14 Rainer TH, Cheng CH, Janssens HJ et al. Oral
prednisolone in the treatment of acute gout: pragmatic,
multicenter, double-blind, randomized trial. Ann Intern
Med 2016;164:464–71.
15 Man CY, Cheung IT, Cameron PA, Rainer TH.
Comparison of oral prednisolone/paracetamol and oral
indomethacin/paracetamol combination therapy in the
treatment of acute goutlike arthritis: a double-blind,
randomized, controlled trial. Ann Emerg Med 2007;49:
670–7.
16 Hill EM, Sky K, Sit M, Collamer A, Higgs J. Does starting
allopurinol prolong acute treated gout? A randomized
clinical trial. J Clin Rheumatol 2015;21:120–5.
17 Taylor TH, Mecchella JN, Larson RJ, Kerin KD,
Mackenzie TA. Initiation of allopurinol at first medical
contact for acute attacks of gout: a randomized clinical
trial. Am J Med 2012;125:1126–34.e7.
18 Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC.
Treatment of acute gouty arthritis in complex
hospitalized patients with anakinra. Arthritis Care Res
2013;65:1381–4.
19 Daoussis D, Antonopoulos I, Yiannopoulos G,
Andonopoulos AP. ACTH as first line treatment for acute
gout in 181 hospitalized patients. Joint Bone Spine 2013;
80:291–4.
20 Pattanaik D, Ali Z, Freire A. AB0880 Acute gouty arthritis
related emergency department visits among US
veterans: characteristics, predictors and areas of
improvement. Ann Rheum Dis 2019;78:1907–8.
21 Hutton I, Gamble G, Gow P, Dalbeth N. Factors
associated with recurrent hospital admissions for gout: a
case–control study. J Clin Rheumatol 2009;15:271–4.
22 Huang IJ, Bays AM, Liew JW. Frequency of allopurinol
dose reduction in hospitalized patients with gout flares. J
Rheumatol 2021;48:467–8.
23 Feng X, Li Y, Gao W. Significance of the initiation time of
urate-lowering therapy in gout patients: a retrospective
research. Joint Bone Spine 2015;82:428–31.
24 Kamalaraj N, Gnanenthiran SR, Kathirgamanathan T et
al. Improved management of acute gout during
hospitalization following introduction of a protocol. Int J
Rheum Dis 2012;15:512–20.
25 Kapadia A, Abhishek A. Inpatient rheumatology
consultation for gout flares and advice to initiate urate
lowering treatment (ULT) in hospital discharge summary
increases ULT prescription in primary care. Joint Bone
Spine 2019;86:271–2.
26 Teichtahl AJ, Clemens L, Nikpour M, Romas E. A
prospective study of acute inpatient gout diagnoses and
management in a tertiary hospital: the determinants and
outcome of a rheumatology consultation. Intern Med J
2014;44:1095–9.
27 Sen M. SAT0443 Reconciliation of urate lowering
therapies during hospitalization and the impact of
rheumatologic consultation on management of inpatient
gout flares. Ann Rheum Dis 2019;78:1310–1.
28 Gnanenthiran SR, Hassett GM, Gibson KA, McNeil HP.
Acute gout management during hospitalization: a need
for a protocol. Intern Med J 2011;41:610–7.
29 Kennedy NJ, Healy PJ, Harrison AA. Inpatient
management of gout in a New Zealand hospital: a
retrospective audit. Int J Rheum Dis 2016;19:205–10.
30 Wright S, Chapman PT, Frampton C et al. Management
of gout in a hospital setting: a lost opportunity. J
Rheumatol 2017;44:1493–8.
31 Barber C, Thompson K, Hanly JG. Impact of a
rheumatology consultation service on the diagnostic









atology/keab539/6319039 by Keele U
niversity user on 14 O
ctober 2021
accuracy and management of gout in hospitalized
patients. J Rheumatol 2009;36:1699–704.
32 Spencer K, Carr A, Doherty M. Patient and provider
barriers to effective management of gout in general
practice: a qualitative study. Ann Rheum Dis 2012;71:
1490–5.
33 Doherty M, Jenkins W, Richardson H et al. Efficacy and
cost-effectiveness of nurse-led care involving education
and engagement of patients and a treat-to-target urate-
lowering strategy versus usual care for gout: a rando-
mised controlled trial. Lancet 2018;392:1403–12.
34 Sun R, Lu J, Li H et al. Evaluation of febuxostat initiation
during an acute gout attack: a prospective, randomized
clinical trial. Joint Bone Spine 2020;87:461–6.
35 Lim AY, Shen L, Tan CH et al. Achieving treat to target
in gout: a clinical practice improvement project. Scand J
Rheumatol 2012;41:450–7.
36 Phang KF, Santosa A, Low BPL et al. A nurse-led,
rheumatologist-assisted telemedicine intervention for
dose escalation of urate-lowering therapy in gout. Int J
Rheum Dis 2020;23:1136–44.
37 Goldfien RD, Ng MS, Yip G et al. Effectiveness of a
pharmacist-based gout care management programme in
a large integrated health plan: results from a pilot study.
BMJ Open 2014;4:e003627.
38 Yokose C, Jorge A, D’Silva K et al. Using electronic visits
(E-visits) to achieve goal serum urate levels in patients with
gout in a rheumatology practice: a pilot study. Semin
Arthritis Rheum 2020;50:1382–6.
39 Mikuls TR, Cheetham TC, Levy GD et al. Adherence and
outcomes with urate-lowering therapy: a site-randomized
trial. Am J Med 2019;132:354–61.
40 Handley MA, Gorukanti A, Cattamanchi A. Strategies for
implementing implementation science: a methodological
overview. Emerg Med J 2016;33:660–4.
41 Michie S, van Stralen MM, West R. The behaviour
change wheel: a new method for characterising and
designing behaviour change interventions. Implement Sci
2011;6:42.
42 Geerligs L, Rankin NM, Shepherd HL, Butow P.
Hospital-based interventions: a systematic review of
staff-reported barriers and facilitators to implementation
processes. Implement Sci 2018;13:36.
43 Schumacher HR, Taylor W, Edwards L et al. Outcome
domains for studies of acute and chronic gout. J
Rheumatol 2009;36:2342–5.









atology/keab539/6319039 by Keele U
niversity user on 14 O
ctober 2021
